Revance to Participate in Upcoming Investor Conferences

NEWARK, Calif., May 21, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq: RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today that the Company will be participating in two upcoming investor conferences.

Revance management is scheduled to present at the Jefferies 2015 Healthcare Conference in New York City on Thursday, June 4 at 1:30pm EDT.

Revance management is also scheduled to present at the William Blair 2015 Growth Stock Conference in Chicago on Wednesday, June 10 at 12:00pm CDT.

Interested parties can access the live audio webcast for both of these conference presentations at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Revance Therapeutics, Inc.

Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. Revance is pursuing clinical development for product candidates topical RT001 and injectable RT002 in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. More information on Revance Therapeutics can be found at www.revance.com.

"Revance Therapeutics", TransMTS® and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

CONTACT: Investors:
         Revance Therapeutics
         Jeanie Herbert
         (714) 325-3584
         [email protected]

         Westwicke Partners
         Leigh Salvo
         (415) 513-1281
         [email protected]

         Trade Media:
         Nadine Tosk
         (847) 920-9858
         [email protected]

You May Also Be Interested In

• AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
• AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and
• Infor Appoints Yuka Kanemitsu as President and Representative Director of Infor Japan to Accelerate Industry Cloud Growth and AI-Driven Business Transformation